
May 21, 2026
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
Recent partnerships among major biopharma companies highlight the growing role of artificial intelligence in drug development, with Eli Lilly, Bristol Myers Squibb (BMS), and Incyte making significant moves to enhance their operations through advanced machine learning technologies.BMS has entered into a collaboration with Anthropic to integrate its Claude AI model into various stages of drug development, including clinical and manufacturing processes. This initiative aims to unlock valuable data









